Generic Name and Formulations:
Oxymetholone 50mg; scored tabs.
- Treatment for Bronchiolitis Obliterans Gains Orphan Drug Status
- Lurbinectedin Gains Orphan Drug Status for Small Cell Lung Cancer
- Nintedanib and Pirfenidone Tolerated in Idiopathic Pulmonary Fibrosis
- Chronic Obstructive Pulmonary Disease Treatments
- Asthma Treatments: Inhalations
- Dosages for the Elderly
Indications for ANADROL-50:
Anemia caused by deficient red cell production. Acquired aplastic anemia, congenital anemia, myelofibrosis, and hypoplastic anemias due to myelotoxic drugs.
Adults and Children:
Individualized. 1–5mg/kg per day for at least 3–6 months; may attempt to lower dose or discontinue after remission. Congenital aplastic anemia: may need continued maintenance dose.
Male breast or prostate carcinoma. Breast cancer in females with hypercalcemia. Nephrosis or the nephrotic phase of nephritis. Severe hepatic dysfunction. Pregnancy (Cat.X).
Peliosis hepatitis. Liver cell tumors. Increased risk of atherosclerosis due to blood lipid changes (eg, decreased HDL, increased LDL).
Not a replacement for other supportive treatments (eg, transfusion; iron, folic acid, Vit. B12, Vit. B6 replacement). Discontinue if jaundice, abnormal liver function, hypercalcemia, or edema occurs. Cardiac, hepatic, or renal dysfunction. Monitor hepatic function, blood, and bone age. Elderly. Young children. Nursing mothers: not recommended.
May potentiate oral anticoagulants. May alter insulin or oral antihyperglycemic needs.
Peliosis hepatis, premature epiphyseal closure in adolescents, edema, hepatic carcinoma, prostatic hypertrophy or carcinoma, gynecomastia, priapism, oligospermia, nausea, jaundice, hirsutism, virilization, male pattern baldness, acne, polycythemia, headache, CNS excitation, insomnia, altered libido, fluid and electrolyte disturbances, suppression of clotting factors, increased serum cholesterol.